CTOs on the Move

Salk Institute

www.salk.edu

 
Unlocking the secrets of life itself is the driving force behind the Salk Institute. Our team of world-class, award-winning scientists pushes the boundaries of knowledge in areas such as neuroscience, cancer research, aging, immunobiology, plant biology, computational biology, and more. Founded by Jonas Salk, developer of the first safe and effective polio vaccine, the Institute is an independent, nonprofit research organization and architectural landmark: small by choice, intimate by nature, and fearless in the face of any challenge.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.salk.edu
  • 10010 North Torrey Pines Road
    La Jolla, CA USA 92037
  • Phone: 858.453.4100

Executives

Name Title Contact Details
Michael Austin
Director of Information Technology Profile
Jerry Sheehan
Chief Information Officer Profile

Funding

Salk Institute raised $25M on 11/21/2016
Salk Institute raised $14.3M on 10/23/2019

Similar Companies

Hohenstein Institute America

Hohenstein Institute America, Inc is a Elon, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Syntron Bioresearch

Syntron Bioresearch, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allogene

Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Founded and led by former Kite Pharma executives who bring unrivaled clinical development acumen in cell therapy, Allogene is well-positioned to further the potential of allogeneic cell therapy for patients. Allogeneic CAR T therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. This approach eliminates the need to create personalized therapy from a patient`s own cells, simplifies manufacturing, and reduces the time patients must wait for CAR T treatment. The Allogene portfolio includes 16 pre-clinical T cell therapy assets and UCART19, an allogeneic CAR T therapy currently in Phase 1 development for the treatment of acute lymphoblastic leukemia (ALL). Through its notable partnerships, Allogene leverages pioneering technology platforms, including TALEN® gene editing technology, to progress its portfolio of immuno-oncology therapies. Allogene, with headquarters in San Francisco, California, is a Two River portfolio company formed with one of the largest Series A financings in biotechnology from an investment consortium that includes TPG, Vida Ventures, BellCo Capital, the University of California Office of the Chief Investment Officer and Pfizer, among others.

Bioverativ

Bioverativ Inc. is an American multinational biotechnology that specializes in the discovery, development, and delivery of therapies for the treatment of haemophilia.

Talis Biomedical

Talis is developing a new class of diagnostic platform to enable rapid, high-complexity testing across a wide range of healthcare settings.